CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 211 enrolled
Drug / intervention
Lurasidone +1 moredrug
Likely dose
Lurasidone 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01421134
NCT01421134Phase 3Completed
CompareCT.gov

A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features

Sumitomo Pharma America, Inc.·interventional·Posted Aug 22, 2011·Updated Jul 15, 2016

In Brief

A Phase 3 clinical trial evaluating Lurasidone and Placebo for Major Depressive Disorder With Mixed Features. Completed, enrolled 211 participants across 43 sites in 5 countries.

Detailed Summary

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder With Mixed Features
CountriesRussia, Serbia, Ukraine, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 22, 2011
Enrollment StartSep 1, 2011
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 14.9 years ago

Interventions

Lurasidonedrug

20, 40, 60 mg, flexible dose, once daily PM 6 weeks

Placebodrug

Placebo